Since the abnormal activation of the HIF-1α/MMPs or HIF-1α/ADAMs signaling pathway leads to sMICA and sMICB, which hinder the killing by NK cells and cause tumor progression and worsening, inhibiting this pathological activation of these signaling pathways is crucial for enhancing the anti-tumor immunity and carrying out immunotherapy. Here, HIF1A is linked to neoplasm.